CYP3A5 *1 allele associated with tacrolimus trough concentrations but not subclinical acute rejection or chronic allograft nephropathy in Japanese renal transplant recipients

[1] Venkataramanan R(1995)Clinical pharmacokinetics of tacrolimus Clin Pharmacokinet 29 404-430

[2] Swaminathan A(2006)CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study Am J Transplant 6 2706-2713

[3] Prasad T(2003)Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus Clin Pharmacol Ther 74 245-254

[4] Jain A(2004)The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant recipients Pharmacogenetics 14 147-154

[5] Zuckerman S(2004)Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients Transplantation 78 1182-1187

[6] Warty V(2005)Impact of CYP3A5 and MDR1 (ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients Transplant Proc 37 1730-1732

[7] McMichael J(2006)Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients Pharmacogenet Genomics 16 659-665

[8] Lever J(2004)The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation Am J Transplant 4 914-919

[9] Burckart G(2007)CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients Clin Pharmacol Ther 82 711-725

[10] Starzl T(1999)Low systemic exposure to tacrolimus correlates with acute rejection Transplant Proc 31 296-298

[1] Venkataramanan R(1995)Clinical pharmacokinetics of tacrolimus Clin Pharmacokinet 29 404-430

[2] Swaminathan A(2006)CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study Am J Transplant 6 2706-2713

[3] Prasad T(2003)Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus Clin Pharmacol Ther 74 245-254

[4] Jain A(2004)The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant recipients Pharmacogenetics 14 147-154

[5] Zuckerman S(2004)Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients Transplantation 78 1182-1187

[6] Warty V(2005)Impact of CYP3A5 and MDR1 (ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients Transplant Proc 37 1730-1732

[7] McMichael J(2006)Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients Pharmacogenet Genomics 16 659-665

[8] Lever J(2004)The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation Am J Transplant 4 914-919

[9] Burckart G(2007)CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients Clin Pharmacol Ther 82 711-725

[10] Starzl T(1999)Low systemic exposure to tacrolimus correlates with acute rejection Transplant Proc 31 296-298